During my time as a Lecturer at UCL researching cancer markers I investigated the role of the cell-cycle protein Mcm5 in the field of urological cancer diagnosis. Since then the technology has been commercialised by Arquer diagnostics Ltd and I have led trials in both prostate and bladder cancer at Southampton and also internationally.

As a result of these trials the ADX Bladder test is now available for use in the private sector and offers patients the chance to avoid invasive cystoscopy during their cancer follow up.